Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.44M 2.24M 2.1M 3.94M 262M 4.01M 26.93M 10.43M 129M 10.41M 10.19M 448M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.72M 8.03M 7.51M 14.09M 937M 14.35M 96.39M 37.33M 462M 37.28M 36.46M 1.6B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2012
Investor Relations Contact - 01/05/2014
Corporate Officer/Principal 77 30/11/2022
Director TitleAgeSince
Chairman 61 01/03/2012
Change 5-day change 1-year change 3-year change Capi.($)
+4.43%+2.49%+61.83%+115.25% 52.88B
+1.58%+14.12%+72.87%+85.18% 50.98B
-0.23%-0.98%-14.12%-16.00% 22.81B
+0.98%+9.05%-0.36%+423.40% 22.43B
-1.81%+5.86%+30.16%-15.37% 17.01B
+0.88%+5.78%+30.82%-34.26% 15.91B
+3.02%+12.74%+143.33%+308.04% 13.58B
+0.68%+2.54%+22.28%+168.03% 13.29B
-0.15%+4.84%+26.58% - 12.56B
Average +1.04%+6.25%+41.49%+129.28% 24.61B
Weighted average by Cap. +1.64%+6.70%+46.21%+120.52%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.06 0.1 6.9 0.11 0.71 0.27 3.4 0.27 0.27 11.82 0.14 0.12 0.11 0.1 0.19 12.77 0.2 1.31 0.51 6.3 0.51 0.5 21.88
Net income -3.1M -2.73M -2.51M -2.35M -4.41M -293M -4.49M -30.15M -11.68M -144M -11.66M -11.4M -502M -18.47M -16.23M -14.95M -13.98M -26.22M -1.74B -26.7M -179M -69.49M -859M -69.38M -67.86M -2.99B
Net Debt 7.1M 6.23M 5.74M 5.37M 10.07M 670M 10.25M 68.9M 26.69M 330M 26.64M 26.06M 1.15B 7.15M 6.28M 5.79M 5.41M 10.15M 675M 10.34M 69.46M 26.9M 333M 26.86M 26.27M 1.16B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-